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The study by Kesler and Blayney1 in this issue of JAMA Oncology investigated the impact 
of anthracycline-based chemotherapy regimens (ANTHR) on cognitive performance and 
resting state functional magnetic resonance imaging (fMRI) brain connectivity within the 
default mode network (DMN) in female breast cancer survivors. Brain connectivity has 
become a major focus in neuroscience that is rapidly translating to the clinical realm where 
brain disorders are viewed from a system or network perspective rather than as a set of 
affected regions. The DMN is of particular interest as a measure of the brain’s resting state 
of spontaneous cognition, or thought processes when not task-focused. Disruptions of the 
DMN have been associated with neurodegenerative disease as well as systemic 
chemotherapy.2 Kesler and Blayney1 found that, compared with breast cancer survivors 
treated with non–ANTHR-based regimens or breast cancer survivors not treated with 
chemotherapy (NC), ANTHR was associated with poorer verbal memory, as well as with 
altered connectivity of the left precuneus region, which is part of the superior parietal lobule 
involved in episodic memory, visuospatial processing, and aspects of consciousness. 
Although the finding of lower connectivity of the left precuneus to other brain regions was 
not specific to the ANTHR group, it was more pervasive. The non-ANTHR group also 
displayed lower connectivity of this brain region to a frontal region compared with NC. This 
finding suggests that different chemotherapy regimens may affect DMN connectivity 
through a similar mechanism, with ANTHR-based regimens having a greater impact, 
perhaps through an oxidative stress-linked metabolic pathway, as posited by the authors.1
The authors1 infer that lower connectivity of the left precuneus with frontal and/or 
hippocampal regions may underlie the poorer memory function of ANTHR-treated 
survivors. Relating the cognitive and imaging findings may have strengthened this argument, 
but correlations between regional connectivity and memory performance were not reported. 
The fact that the non-ANTHR group also showed lower connectivity of the left precuneus 
with a frontal region but did not show decreased verbal memory performance suggests other 
contributory factors. A subset of patients included in this study1 also completed task-based 
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fMRI. While those results are not included their article, future work integrating task-based 
fMRI (eg, during episodic memory processing) would be another potential source of 
convergent data for the authors’1 hypothesis that altered precuneus connectivity may relate 
to reduced post-ANTHR memory function. Although task-based analysis may have been 
outside the scope of the current work,1 future fMRI studies analyzing memory-induced 
connectivity changes in relation to task performance could support the authors’1 
interpretation that DMN connectivity is related to cognitive dysfunction. The integration of 
structural and functional neuroimaging and performance-based measures of cognitive 
dysfunction is an ongoing effort in cancer- and treatment-related neurocognitive dysfunction 
research, as well as in neuroimaging research more broadly.
In addition to verbal memory, the authors1 examined neuropsychological measures of 
executive function and verbal fluency, neither of which showed significant differences 
between groups, although the combined chemotherapy-treated groups showed a trend toward 
lower executive function compared with the NC group. These findings suggest that while 
chemotherapy regimen may be an important factor in some types of cognitive dysfunction 
(eg, episodic memory), changes in other cognitive domains may be common to a wider 
range of treatment regimens, emphasizing the need for studies characterizing the types of 
cognitive dysfunction linked with various chemotherapy protocols.
Other findings from the study by Kesler and Blayney1 included similar elevation of patient-
reported cognitive dysfunction and psychological distress in both chemotherapy-treated 
groups compared with the NC group. Future investigation of the relationship between 
subjective symptoms and connectivity measurements may help elucidate mechanisms 
driving cognitive concerns after cancer treatment. Understanding this aspect of posttreatment 
symptomatology would be particularly useful given the finding that both chemotherapy-
treated groups showed subjective symptom elevation compared with the NC group, despite 
the lack of performance deficits in the non-ANTHR group. While this could in part be 
attributable to relatively small sample sizes, a common challenge for neuroimaging studies, 
it also highlights broader issues in this research area. Prior studies examining cancer- and 
treatment-related cognitive effects have shown cognitive changes in patient subsets, with a 
lack of consistency between subjective and objective cognitive changes. The work of Kesler 
and Blayney1 provides important insight into which patients may be more likely to show 
objective cognitive changes, while the reconciliation of subjective and objective cognitive 
changes remains a challenge in this and other populations.
Interestingly, Kesler and Blayney1 found that the dose of ANTHR was not associated with 
either cognitive performance or resting functional connectivity, suggesting that relatively 
small differences in standard-dose chemotherapy regimens may not have a significant impact 
on the degree of cognitive dysfunction compared with previous studies comparing low- and 
high-dose chemotherapy effects.3 In addition, endocrine treatment was not associated with 
either outcome; however, as the authors1 suggest, this could be due to the high percentage of 
treated patients in each group (>60%), limiting power for the analysis. Disease stage was 
also not associated with either outcome, though there was a significant difference in stage 
distribution between groups, as expected by indication for chemotherapy. This is particularly 
important in light of studies that have shown differences in brain function during task-based 
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fMRI between healthy controls and patients with cancer prior to systemic treatment, 
suggesting that aspects of the cancer disease process or risk factors also may contribute to 
cognitive dysfunction.4–6 Immune activation has increasingly been posited as a mechanism 
for these changes. This hypothesis has been supported by research showing that memory 
performance was correlated with alterations in proinflammatory cytokines in patients newly 
diagnosed as having breast cancer prior to treatment.7 Additional prospective studies are 
needed to address baseline differences and the impact of specific treatments on cognitive 
function, the underlying neural substrate, and specific biological pathways.8 Resolving the 
pathways leading to cognitive dysfunction will be important for development of targeted 
interventions.
While previous studies have linked chemotherapy and cognitive decline, and a few other 
studies have linked treatment with differences in brain connectivity,2,9,10 there has been very 
little research comparing cognitive effects of different types and combinations of 
chemotherapy because most studies have been underpowered to distinguish these effects. 
This present study1 builds on preclinical work11 and, although modest in power to detect 
regimen differences, represents an important step forward while underscoring the need for 
larger studies.
Neuroimaging studies have advanced research on cancer and cognitive dysfunction in recent 
years, providing a biological context to prior neuropsychological and self-report studies. 
Findings from prospective breast cancer cohorts have shown both cancer- and treatment-
related gray matter alterations12 and demonstrated a relationship between lower frontal gray 
matter density and increased cognitive complaints13 and reduced cerebral perfusion.14 
Prospective task-based fMRI studies have also shown cancer- and treatment-related brain 
activation changes and have been able to demonstrate correspondence of changes in 
structure and function in frontal brain regions that may underlie the commonly observed 
cognitive changes in this population.5 However, pretreatment and posttreatment analysis of 
resting cerebral perfusion has also shown regions of increased perfusion in patients who 
received chemotherapy, which correlated with pretreatment neuropsychological 
performance.14 These findings emphasize the complex nature of cancer and treatment-
related neural changes and underscore the possibility that different physiological 
mechanisms may be involved in various aspects of these cognitive and brain changes, as also 
noted by Kesler and Blayney.1 Given the diverse brain regions reported in various imaging 
studies as significantly associated with cancer and chemotherapy, the study of connectomics 
is a logical extension that may integrate these findings into a more coherent picture of 
alterations in brain network function and cognition related to cancer and its treatment. It will 
be important for future studies to consider the impact of cancer and related treatments on 
other known functional brain networks, in addition to the DMN, to gain a more complete 
understanding of the impact of cancer and treatment on brain function.
Larger, prospective studies are needed, including different studies in patients with types of 
cancer as well as healthy controls to provide a normative framework so that cancer-specific 
effects can be identified. In addition to allowing further discrimination of specific treatment 
regimen effects, larger studies would permit investigation of other patient-specific factors 
likely to contribute to posttreatment cognitive outcomes, including genetic variability. With 
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the movement toward precision medicine, it will be important to investigate genetic 
predictors of cognitive risk for various regimens. Similarly, the roles of cognitive aging and 
neurodegenerative disorders of aging are largely unexplored in cancer imaging and 
biomarker studies. Different types of chemotherapy may specifically exacerbate neurotoxic 
processes present in normal aging and/or neurodegenerative disorders such as Alzheimer or 
Parkinson disease. Kesler and Blayney1 discuss elevated molecular markers of aging in 
patients with breast cancer after ANTHR treatment,15 as well as the theoretical link between 
ANTHR-increased oxidative stress and amyloid β accumulation, which could accelerate the 
progression of Alzheimer disease. However, to date, specific treatment types have not been 
compared for effects on these important pathways, which have the potential to have a 
significant impact on survivor quality and length of life. The study by Kesler and Blayney1 
in this issue therefore provides intriguing hypotheses warranting follow-up in larger 
prospective studies.
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